RNXT Share Price Performance
US$1.29
0.28 (27.12%)
69.3% undervalued intrinsic discount
US$4.20
Fair Value
Price US$1.29
Stock_Research_Today US$4.20
Fair ValueUS$4.20
Share PriceUS$1.29
69.3% undervalued intrinsic discount
RenovoRx, Inc. Stock Price
- 1 Narratives written by author
- 3 Comments on narratives written by author
- 231 Fair Values set on narratives written by author
RNXT Community Narratives
ST
Fair Value US$4.2 69.3% undervalued intrinsic discount
Revolutionizing Cancer Treatment
16users have liked this narrative
3users have commented on this narrative
125users have followed this narrative
Revolutionizing Cancer Treatment
A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.
16users have liked this narrative
3users have commented on this narrative
125users have followed this narrative
ST
US$4.2
69.3% undervalued intrinsic discount
Stock_Research_Today Fair Value
Revenue growth
371.3% p.a.
Profit Margin
36%
Future PE
15x
Share price in 2029
US$3.98
Snowflake Analysis
RenovoRx, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.29
- 62.84%
- -1,610.88%
- 0%
About RNXT
- Founded
- 2009
- Employees
- 10
- CEO
- WebsiteView website
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
